Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Cancer
Breast Neoplasms
First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
35
Registration Number
NCT00001384
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Breast Neoplasms
First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT00001498
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1
Terminated
Conditions
Breast Neoplasms
Metastases, Neoplasm
First Posted Date
2002-11-11
Last Posted Date
2012-04-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
37
Registration Number
NCT00048893
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

First Posted Date
2002-11-08
Last Posted Date
2013-06-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
70
Registration Number
NCT00048737
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

First Posted Date
2002-08-16
Last Posted Date
2017-05-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT00043979
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

Phase 1
Terminated
Conditions
Scleroderma
Systemic Sclerosis
First Posted Date
2002-07-10
Last Posted Date
2007-12-28
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Target Recruit Count
15
Registration Number
NCT00040651
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

First Posted Date
2002-06-28
Last Posted Date
2020-01-18
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
15
Registration Number
NCT00040469
Locations
🇺🇸

Texas Children's Hospital, Houston, Texas, United States

🇺🇸

The Methodist Hospital, Houston, Texas, United States

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

Phase 2
Completed
Conditions
Multiple Sclerosis
First Posted Date
2002-06-28
Last Posted Date
2020-01-18
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
10
Registration Number
NCT00040482
Locations
🇺🇸

The Methodist Hospital, Houston, Texas, United States

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

First Posted Date
2002-06-07
Last Posted Date
2011-11-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
65
Registration Number
NCT00038844
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

First Posted Date
2002-06-04
Last Posted Date
2015-09-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
54
Registration Number
NCT00038610
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy